Last edition
News about "Frank Jiang"
Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893
Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.
Frank Jiang | 06/09/2025 | By Mrinmoy Dey
Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.
Frank Jiang | 28/07/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy